The country does not have the drugs needed for cancer patients, and the batch purchased in 2021 quickly sold out. This was announced by the Acting General Director of the State Enterprise "

According to him, the shortage of medicines arose due to the fact that information on needs was collected in Excel format from health departments, and not from MedData”.

" It is impossible to fix this situation in a day.. A striking example is Oxaliplatin.. In 2021, its quantity before purchase was scarce. Now this batch has arrived, and we can safely write in social networks that we have completed the order. That is, everything that was ordered - bought. But the bottom line is that this batch ended very quickly, and there is no Oxaliplatin in the country,"

[see_also ids\u003d"

The Ministry of Health expects that a new batch of the drug, purchased in 2022, will arrive in January.

As for medicines for orphan diseases, the situation is better here.. In addition to the drug for spinal muscular atrophy, several other drugs were purchased under the OKD, which were purchased much cheaper thanks to the OKD.

“We were able to cover the need for orphan diseases by 100%, and all patients are guaranteed to receive them,” Adamanov said..

Read more about the new rules of centralized procurement-2023; about their budget;

about why patients are not 100% provided with medicines in some central procurements and what this leads to; why medicines take so long to get to the hospital and what the Ministry of Health plans to do to speed up these processes under the law, which allows you to limit the purchase of medicines from companies that have manufacturing plants in Russia, and read about many other things in Alla Kotlyar’s interview with and. Director General of Medical Purchase Edem Adamanov.